Keros Therapeutics, Inc. (KROS)
9.36
-0.09
(-0.95%)
USD |
NASDAQ |
Nov 06, 16:00
9.315
-0.04
(-0.48%)
After-Hours: 20:00
Keros Therapeutics Shareholders Equity (Quarterly) : 262.32M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 262.32M |
| March 31, 2026 | 285.63M |
| December 31, 2025 | 303.13M |
| September 30, 2025 | 703.58M |
| June 30, 2025 | 706.73M |
| March 31, 2025 | 728.87M |
| December 31, 2024 | 571.55M |
| September 30, 2024 | 532.84M |
| June 30, 2024 | 420.92M |
| March 31, 2024 | 453.95M |
| December 31, 2023 | 332.21M |
| September 30, 2023 | 295.84M |
| June 30, 2023 | 326.26M |
| March 31, 2023 | 354.98M |
| Date | Value |
|---|---|
| December 31, 2022 | 277.42M |
| September 30, 2022 | 241.02M |
| June 30, 2022 | 211.21M |
| March 31, 2022 | 223.49M |
| December 31, 2021 | 243.17M |
| September 30, 2021 | 218.48M |
| June 30, 2021 | 235.66M |
| March 31, 2021 | 248.37M |
| December 31, 2020 | 261.72M |
| September 30, 2020 | 130.76M |
| June 30, 2020 | 141.36M |
| March 31, 2020 | -24.87M |
| December 31, 2019 | -19.45M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Agios Pharmaceuticals, Inc. | -- |
| Viking Therapeutics, Inc. | 588.60M |
| Protagonist Therapeutics, Inc. | 841.54M |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 287.60M |
| Total Liabilities (Quarterly) | 25.28M |
| Debt to Equity Ratio | 0.0599 |
| Current Ratio | 21.96 |
| Net Debt Paydown Yield | 0.25% |